NTRK1 and hematologic disorder: Indeed, NK-92 engineering with CARs to CD19/CD20 or disialoganglioside GD2, HER2 receptor tyrosine kinase, and epidermal growth factor receptor EGFR, disclosed higher activity against hematological malignancies [31,33,34] or solid tumors [7,35,36,37].